Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the pegfilgrastim biosimilars market size evolved in recent years?

In recent years, the market size for pegfilgrastim biosimilars has experienced swift expansion. The expectations are for it to rise from $1.56 billion in 2024 to reach $1.8 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.3%. The historic growth of this sector is primarily due to factors such as higher incidence of cancer, government policy initiatives, elevated healthcare spending, increased investment in biopharmaceutical research and development, the affordability of biosimilars, and extensive usage of these biosimilar drugs.

What are the predictions for the pegfilgrastim biosimilars market size in the coming years?

The market size of medical device outsourcing is projected to experience swift expansion in the forthcoming years. It is estimated to reach up to $290.76 billion in 2029 at a compound annual growth rate (CAGR) of 15.6%. The surge during the projected period is due to the concentration on core competencies, reduction in time-to-market requirements, cost-effectiveness in manufacturing, need for scalability and flexibility, and the growing intricacy of medical devices. Notable trends expected in this period encompass the increase in customization and personalization, emphasis on risk reduction and compliance, escalating demand for remote monitoring devices, heightened focus on data security, and innovative advancements in wearable medical devices.

Get your pegfilgrastim biosimilars market report here!

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

What key factors are fueling the growth of the pegfilgrastim biosimilars market?

Initiatives undertaken by the government to facilitate the growth of biosimilars, are projected to propel the pegfilgrastim biosimilars market. Governments around the world are putting an emphasis on biosimilar development, spurred by their affordability. The US Food and Drug Administration (FDA), for instance, initiated a Biosimilar Action Plan to expand treatment alternatives. The Australian government has shown dedication to the Biosimilar Awareness Initiative and further bolstered their commitment by financially supporting the Generic and Biosimilar Medicines Association with a grant worth $5 million. This step is aimed at fostering a broader understanding of biosimilars and encouraging the appropriate prescription, dispensing, and use of these medicines. As a result, such government-led efforts for the promotion and development of biosimilars contribute to both increased manufacturing and awareness, which somehow stimulates the expansion of the pegfilgrastim biosimilars market.

How is the global pegfilgrastim biosimilars market divided into key segments?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia, Other Supportive Therapies in Oncology

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Who are the key firms paving the way for growth in the pegfilgrastim biosimilars market?

Major companies operating in the pegfilgrastim biosimilars market include Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Reddy’s Laboratories, Shanghai Henlius Biotech, Alvotech, EirGenix, Bharat Biotech, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Which trends are expected to transform the pegfilgrastim biosimilars market?

Businesses in the pegfilgrastim biosimilar market are heightening their product ingenuity via cooperative collaborations. In an effort to remain relevant in an ever-growing competitive marketplace, these businesses are creating groundbreaking products and dividends their knowledge and proficiency with their counterparts. The trend of partnering or signing out-licensing deals with education and research institutions has been prevalent for some time in this market and has seen a significant rise recently. For example, in May 2023, a noteworthy collaboration was seen between Amneal Pharmaceuticals, a US-based generics, and specialty pharmaceutical firm, and Kashiv Biosciences, a US-based comprehensive biosciences business. The collaboration aimed at developing and launching Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. FYLNETRA, a preservative-free, transparent solution, comes in a 6 mg/0.6 mL single-dose pre-filled syringe and helps lessen infection threats, particularly febrile neutropenia, in patients suffering from non-myeloid cancers who are undergoing specific myelosuppressive anti-cancer treatments.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4015

What regions are contributing significantly to the growth of the pegfilgrastim biosimilars market?

North America was the largest region in the pegfilgrastim biosimilars market in 2024. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Biosimilar Hormones Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report

Oral Biologics & Biosimilars Global Market Opportunities And Strategies To 2030

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Rituximab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: